GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

Event free survival

Time frame: up to 10 years

Hematologic remission rate

Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis

Molecular remission rate

Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis

Positron Emission Tomography (PET) based remission evaluation

Time frame: after induction and consolidation, approximately 6 - 8 weeks from diagnosis

Remission duration

Time frame: up to 10 years

Relapse rate

Time frame: up to 10 years

Disease free survival

Time frame: up to 10 years

Early mortality

Time frame: during induction therapy with a duration of approximately 6 - 8 weeks

Mortality in Clinical Remission (CR)

Time frame: up to 10 years

Comorbidities

Time frame: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified

Quality of life assessed by Quality of Life Questionnaire (QLQ-C30)

Time frame: after treatment which is approximately 2.5 years from diagnosis

Eastern Cooperative Oncology Group (ECOG) status

Time frame: Time of diagnosis and up to 10 years during regular follow-up requests which are not pre-specified

Toxicities assessed by CTCAE v4.03

Time frame: during treatment with an approximate duration of 2.5 years from diagnosis